AMG 557

a fully human antibody directed against the inducible T cell costimulator ligand (ICOSL)

Networked: 2 relevant articles (1 outcomes, 2 trials/studies)

1.	Autoimmune Diseases (Autoimmune Disease) 01/01/2016 - "The selective reduction in anti-KLH IgG demonstrates a PD effect of AMG 557 in subjects with SLE consistent with the biology of the ICOS pathway and supports further studies of AMG 557 as a potential therapeutic for autoimmune diseases. "
2.	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/01/2018 - "Brief Report: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis." 01/01/2016 - "To evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single-dose and multiple-dose administration of AMG 557, a human anti-inducible T cell co-stimulator ligand (ICOSL) monoclonal antibody, in subjects with systemic lupus erythematosus (SLE). "
3.	Arthritis (Polyarthritis) 01/01/2018 - "Brief Report: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis."

1.	Immunoglobulin G (IgG)
2.	Inducible T-Cell Co-Stimulator Ligand
3.	Monoclonal Antibodies